Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B

Inclusion Criteria: * Female or male, 18 to 65 years of age, inclusive * Chronic hepatitis B * Not treated with anti-viral therapeutics including interferon or pegylated interferons for more than 12 weeks before Screening * Not treated with anti-viral therapeutics including interferon or pegylated interferons 6 months within Screening * Compensated chronic hepatitis B * HBeAg positive or HBeAg negative * Elevated serum ALT level (1.2-10 X ULN, inclusive) Exclusion Criteria: * Co-infection with hepatitis C or D virus (HCV or HDV) or HIV * Decompensated liver disease * Creatinine clearance (calculated by Cockroft-Gault formula) less than 50 ml/min * Screening alpha-fetoprotein (AFP) value greater than or equal to 50 ng/mL, and a follow-up ultrasonography performed prior to baseline shows findings indicative of HCC * Treatment with immunomodulatory agent or corticosteroids within 6 months prior to study entry. * Pregnancy or breast-feeding * Patient is currently abusing alcohol or illicit drugs * Significant systemic illnesses other than liver diseases * Presence of other causes of liver disease * A history of organ transplantation Presence of anti-HBs at screening